Industry News: PerkinElmer to Display Multimodality Imaging Solutions and Present Expertise at 2015 WMIC Annual Meeting

PerkinElmer is a leader in preclinical imaging enabling researchers to visualize disease in all its dimensions

01 Sep 2015


PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it will showcase its multimodality imaging technologies at the 2015 World Molecular Imaging Congress (WMIC) Annual Meeting. The event brings together research scientists to discuss and present cutting-edge advances in molecular imaging.

PerkinElmer's portfolio of preclinical imaging offerings include optical, microCT and PET imaging modalities, along with a wide range of in vivo imaging reagents. These solutions enable visualization in multiple dimensions, providing researchers a better understanding of disease.

"WMIC 2015 is an ideal forum for PerkinElmer to share its innovative preclinical solutions and expertise with the molecular imaging community," said Brian Kim, President, Life Sciences & Technology, PerkinElmer. "Combining modalities helps researchers monitor disease progression, determine treatment efficacy early on, and more deeply understand the metabolic changes occurring throughout disease development -- which may translate to improved health outcomes."

PerkinElmer will showcase the following imaging technologies at WMIC 2015:

  • IVIS® SpectrumCT™: an integrated optical and microCT system that enables simultaneous molecular and anatomical imaging in one platform
  • Quantum™ GX microCT system: small animal microCT instrument providing high-resolution images at an X-ray dose low enough to enable true longitudinal imaging capability
  • G8 PET/CT imaging system: integrates PET and CT into a bench top system built to enable preclinical workflows in a broad-range of applications
  • Solaris™ Open Air Fluorescence Imaging System: designed for large animal preclinical, translational and emerging veterinary surgical research applications
  • Optical imaging reagents: including the new Bioware® Brite bioluminescent oncology cell lines and fluorescence agents
  • ImmunoPET reagents: including Zirconium-89 and Iodine-124